INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo ISOPTIN®120 mg
SCHEDULING STATUS:
S3

PROPRIETARY NAME
(and dosage form):

ISOPTIN®120 mg
Film-coated tablets

COMPOSITION:
Each film-coated tablet contains 120 mg verapamil hydrochloride.

PHARMACOLOGICAL CLASSIFICATION:
7.1.4 Vasodilators - Coronary and other medicines used in Angina pectoris.

PHARMACOLOGICAL ACTION:
The calcium antagonist verapamil reduces myocardial oxygen consumption in vitro directly by intervening in the energy consuming metabolic processes of the myocardial cell, and indirectly by diminishing the peripheral resistance (afterload).
It prolongs impulse conduction in the AV node.

INDICATIONS:
Angina pectoris, supraventricular tachydysrhythmia. Prophylaxis of relapses after electrocardioversion.

CONTRA-INDICATIONS:
Retarded AV conduction (second and third degree AV block), acute stage of myocardial infarction, sick-sinus syndrome.

DOSAGE AND DIRECTIONS FOR USE:
The doses of Isoptin as prescribed by the physician are to be taken regularly, preferably half an hour before meals together with some liquid. The average daily dose is 120 mg - 360 mg in three divided doses where possible.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
As Isoptin inhibits AV conduction, it may cause AV block. Isoptin may also lead to a transient decrease in blood pressure, even in normotensive patients.
Constipation, headache, fatigue, palpitations, first and second degree AV block, SA block, epigastric pain, flush, dizziness, urticaria and temporary skin rash may occur. Reversible increase of transaminases and/or alkaline phosphatase has been observed and is most probably a response to allergic hepatitis. Reports of individuals experiencing exacerbation of arthritis, increased urination, burning sensation of the gums, mild tremor and severe facial pain are known.
Where heart failure is present, full compensation with cardiac glycosides must be achieved before the administration of Isoptin.
In patients with diminished hepatic function (parenchymal loss/reduced blood supply) the effect of Isoptin is intensified and prolonged depending on the severity of the disease due to impaired drug metabolism. In these cases dosage should be adjusted with special care.
In atrial fibrillation and simultaneous WPW syndrome there is a risk of precipitating ventricular fibrillation.
Safety in pregnancy has not been established.
Interactions
During the simultaneous administration of Isoptin and drugs with cardio-depressive effect and/or inhibiting effect on atrioventricular conduction (e.g. beta-adrenergic blockers), the patient should be observed for additive effects.
Isoptin may intensify the blood pressure lowering effect of antihypertensives, and this makes it often possible to reduce the dose of the antihypertensives, particularly in patients on long-term treatment with Isoptin.
Rises in digoxin plasma levels under concomitant administration of Isoptin have been reported. However, extensive experience indicates that this possible interaction is of only slight clinical relevance. Physicians should be alert for symptoms of possible digitalis intoxication.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
Cardiac arrest: External cardiac massage, artificial respiration, ECG for differentiating between asystolia and ventricular fibrillation; then appropriate intensive measures, such as defibrillation or pacemaker therapy, as required.
Second and third degree AV block: Atropine, Isoproterenol, if necessary pacemaker therapy.
Development of myocardial insufficiency: Dopamine, dobutamine, cardiac glycosides or calcium.
Hypotension: Proper positioning, dopamine, dobutamine, norepinephrine.

IDENTIFICATION:
White biconvex film-coated tablets. Embossed with “Isoptin 120”on the front and “Knoll”on the back.

PRESENTATION:
50 tablets of Isoptin 120 mg (glass bottles).

STORAGE INSTRUCTIONS:
Store in a cool (below 25°C) dry place. Keep out of reach of children

REGISTRATION NUMBER:
R/7.1.4/195

NAME AND BUSINESS ADDRESS OF THE APPLICANT:
Knoll Pharmaceuticals South Africa (Pty) Ltd..
P.O. Box 3030
Halfway House
1685

        Logo

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
01.09.90

        6061
        C/00

Updated on this site: October 2001

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2004